Dr. Susan Rohrer has over 20 years of experience in the pharmaceutical industry. Before joining Merck's Licensing organization in 2004, she served as Senior Director of Biology / Drug Discovery in the Merck Research Laboratories where she studied the mechanism of action of ivermectin, the role of somatostatin receptors in diabetes and selective estrogen receptor modulators for hormone replacement therapy. Within the Licensing and External Research department at Merck, Susan chaired the Neuroscience Review and Licensing Committee. Her recent major licensing deals include Neuromed (NMED-160), Gladstone Institute of Neurological Disease (ApoE mechanisms in neurodegenerative diseases), Addex mGluR5 (schizophrenia) and Addex mGluR4 (Parkinson's disease). Susan's current role within Merck's External Scientific Affairs Department is Licensing Scout for the Mid-Atlantic and Midwest US. She is a graduate of the University of Michigan (BS) and the University of Notre Dame (PhD).
To RSVP, Contact Susan Engelhardt, Center for Innovative Ventures of Emerging Technologies (CIVET) 732-445-4500 x6283, email@example.com, www.civet.rutgers.edu